Tandem Diabetes Care (NSDQ:TNDM) shares took a hit after hours today on third-quarter results that were mixed compared to the consensus forecast. The San Diego-based insulin delivery and diabetes technology company posted losses of -$9.4 million, or -15¢ per share, on sales of $123.6 million for the three months ended Sept.30, 2020, for a bottom-line slide […]
MassDevice Earnings Roundup
Insulet surpasses Q3 earnings estimates, raises guidance
Insulet (NSDQ:PODD) posted third-quarter results after market close yesterday that beat analysts’ consensus for the company. The Acton, Mass.-based tubeless insulin pump manufacturer announced profits of $11.6 million or $0.17 per share on sales of $234 million for the three months ended September 30, 2020, for a bottom-line gain of 13.5% on sales growth of 21% compared […]
Dexcom down big despite strong Q3, raised guidance
Dexcom (NSDQ:DXCM) shares took a big hit today on third-quarter results that trounced the consensus forecast. Shares of DXCM were down nearly -9% at $346.51 per share in mid-morning trading yesterday. Today, DXCM is trading down -3.2% $338.10. The San Diego-based insulin delivery technology developer posted profits of $72.2 million, or 73¢ per share, on sales […]
West Pharmaceuticals dips despite strong Q3, raised guidance
West Pharmaceutical Services (NYSE:WST) shares dipped slightly despite third-quarter results that topped the consensus forecast. The Exton, Pa.-based company posted profits of $82.3 million, or $1.09 per share, on sales of $548 million for the three months ended Sept. 30, 2020, for a 46.2% bottom-line gain on sales growth of 0.3%. Adjusted to exclude one-time items, […]
Nemaura Medical dips on Q1 losses
Nemaura Medical (NSDQ:NMRD) shares took a slight hit today on first-quarter results that reflected losses of over $1 million. The Loughborough, England-based continuous glucose monitor maker did not report its revenue numbers for the quarter, having posted losses of $1.1 million, or -5¢ per share for the three months ended June 30, 2020, for a 12.1% […]
Insulet up on Street-beating Q2, raised guidance
Insulet (NSDQ:PODD) shares ticked up today on second-quarter results that topped the consensus forecast. The Acton, Mass.-based wearable insulin delivery system developer posted profits of $14.4 million, or 22¢ per share, on sales of $226.3 million for the three months ended June 30, 2020, for a bottom-line gain of nearly ten times as much as last […]
Thermo Fisher rises on COVID-19 response-driven Q2
Thermo Fisher Scientific (NYSE:TMO) shares got a boost today on second-quarter results that came in well above the consensus forecast. The Waltham, Mass.-based company posted profits of $1.2 billion, or $2.90 per share, on sales of $6.9 billion for the three months ended June 27, 2020, for a 3.3% bottom-line gain on sales growth of 9.5%. […]
Thermo Fisher projects 10% increase in Q2 sales
Thermo Fisher Scientific (NYSE:TMO) announced today that it estimates revenue growth for its recently ended second quarter to total approximately 10%. Waltham, Mass.-based Thermo Fisher said in a news release that its reported and organic sales growth for the quarter (ended June 27) was primarily driven by global sales of PCR-based tests and other products and […]
Insulet down after hours on Q4 sales beat, bottom-line slide
Insulet (NSDQ:PODD) shares sunk after hours today on fourth-quarter results that beat the consensus forecast for revenue but appeared to miss on earnings. The Acton, Mass.–based insulin delivery device maker posted profits of $5 million, or 8¢ per share, on sales of $209.4 million for the three months ended Dec. 31, 2019, for a 49.5% bottom-line […]
Insulet Q3 earnings beat The Street despite bottom-line slide
Insulet (NSDQ:PODD) shares are rising today on third-quarter results that topped the consensus forecast, despite a dip in profits. The Acton, Mass.–based company posted profits of $852,000, or 1¢ per share, on sales of $192.1 million for the three months ended Sept. 30, for a 48.6% bottom-line slide on sales growth of 27.1%. Adjusted to exclude […]
